View All     Post Message

Hot Topics Categories

Aging

Alternative Medicine

Big Pharma

Children's Health

Consumer Products and Services

Diseases and Conditions

Drug Talk

eDrugSearch.com Testimonials

Everything Else

Food and Drug Administration

Health 2.0

Health Insurance

Healthcare100

Humor

Inspirational

Introduce Yourself

Medications

Men's Health

News and Media

Pharmacy Talk

Public Health and Safety

Religion and Spirituality

Reproductive Health

Senior Health

Suggest a Category

Using eDrugSearch.com

Weight Loss Tips and Issues

Women's Health


Food and Drug Administration > Avandia Debacle Prompts FDA to Consider New Rules for Approving Diabetes Drugs

  Posted By

June 30, 2008, 4:22 pm
Flag as Inappropriate
ewills  

  Subject

Avandia Debacle Prompts FDA to Consider New Rules for Approving Diabetes Drugs 

  

Federal regulators are mulling over new rules for approving diabetes drugs. The new regulations the Food & Drug Administration (FDA) is considering include requiring that new diabetes drugs have a positive impact on cardiovascular disease and life span. The push for new rules comes a little over a year after a study found that Avandia - a popular diabetes drug marketed by GlaxoSmithKline - raised cardiovascular risks and probably did little to improve the life span of the people taking it.

Avandia has been a subject of controversy since May 2007, when an analysis of 42 clinical trails published by the Cleveland Clinic showed that patients taking the drug had a 43-percent higher risk of having a heart attack. In June 2007, Congress held hearings to discuss the FDA’s handling of its safety issues. At those hearings, it was revealed that in 2005 GlaxoSmithKline had informed the FDA of a study it had conducted that produced similar results. However, both the agency and the manufacturer felt that more investigation was needed before conclusions could be made about Avandia’s possible safety issues. Thus, the public was not made aware of the Avandia heart attack risk until the publication of the Cleveland Clinic article.

Currently, the FDA requires the makers of diabetes drugs to prove they lower blood sugar levels. This outcome is known as a surrogate endpoint, because it was thought that lowering blood sugar would have a positive effect on cardiac risks and life span - the true goals of a diabetes drug. But the Avandia debacle has led many experts to call on the agency to require drug makers to meet other bench marks, including whether they reduce the risk of cardiovascular problems - the number one killer of diabetics.

The issue of what benchmarks the FDA should use to approve diabetes drugs will be the topic of a special two-day meeting of FDA officials and outside medical experts set to start Tuesday. The FDA will also consider if the makers of diabetes drugs currently on the market, including Glaxo, should conduct additional studies on whether there are long-term cardiac risks with their products. According to The Wall Street Journal, scheduled speakers at the meetings include several doctors who have questioned the validity of surrogate end points. One, cardiologist Steven Nissen of the Cleveland Clinic, authored a 2007 Avandia study.

The practice of allowing surrogate endpoints to approve new drugs was also questioned this year when Vytorin, a blockbuster cholesterol lowering medication, was found to be ineffective in preventing clogged arteries. Vytorin had been approved on the basis that it lowered bad cholesterol. It was thought that would correlate to a decrease in the amount of arterial plaque in patients taking the drug. But a study released in January showed that assumption to be wrong.

Source
http://www.newsinferno.com/archives/3367 

Comments

 

June 30, 2008, 6:21 pm
Flag as Inappropriate
jimmys devoted says...

  

when avandia and actos came under fire years ago my doctor and i looked at alternatives.. we looked at what teh drug was supposed to and waht was out theer alraedy that can do teh same thing and have a spoitive impact on other fronts.
after much head scratchinga dn book looking we disocvered that after reading countless papers that these drugs do the same as vitamins that sensitize muscles to use glucose properly....
vitamins,, what a novel idea.

so thast where we began. adjusting doses and finally coming up with avitamin regimine thatw roks teh same as these with extra benefits....

then we added chromium and well it became rocket fuel... my food was being used, my glucose was down and my plaque dropped.....

thsi is clearcase of pateint doctor relationship.
that was 5 years ago...

so i think in an effort for drug companies to get teh revenues they dont take the time to actually read whats put in front of them......
 

 

July 1, 2008, 7:14 am
Flag as Inappropriate
skatss says...

  

Too many times I have seen drugs that are at first touted to be the best thing that has been discovered for diabetics and for the overweight and the like, that soon become deadly as people demand that they get a prescription for it and then fall victim to bad side effects. That has happened to drugs for diabetics and for the overweight too among others.

My doctor is the exact opposite of many doctors. He almost always refuses to give me a prescription for any new drug unless he knows for sure that it will not harm me.

Twenty some odd years ago when I was diagnosed with diabetes, my doctor refused to let me take a popular oral medication because he had heard rumors that people taking it had heart troubles afterwards. He put me on insulin right away and I wasn't thrilled. But because of that decision, I think that it was possible that I am off all medication for diabetes now and can control it well with diet.

I just wish that there was some way that drug companies would be forced to show the public all the results of its studies on their new drugs. If people knew that they could lose their health because the drug might do one thing to help but might also harm them, I doubt that so many people would clamor to take every new drug that advertised as a miracle. 

 


What do you think?

Enter Your Reply

 
 

    Notify me of follow-up comments via email